Literature DB >> 10550222

Anti-phospholipid antibodies in HIV infection and SLE with or without anti-phospholipid syndrome: comparisons of phospholipid specificity, avidity and reactivity with beta2-GPI.

C Petrovas1, P G Vlachoyiannopoulos, T Kordossis, H M Moutsopoulos.   

Abstract

Increased prevalence of anti-phospholipid antibodies (aPL) and increased levels of lipid peroxidation have been described in patients with HIV infection. To assess the binding specificity and avidity of aPL antibodies in HIV infection, sera from 44 HIV-1 infected patients were evaluated for antibodies to cardiolipin (aCL), phosphatidyl serine (aPS), phosphatidyl inositol (aPI) and phosphatidyl choline (aPC) using enzyme linked immunosorbent assay (ELISA) methods. Sera from 30 patients with systemic lupus erythematosus (SLE), but without features of anti-phospholipid syndrome (APS) (SLE/non APS), six with SLE and secondary APS, (SLE/APS) and 11 with primary APS (PAPS) were also evaluated as controls. The resistance of the aPL antibody binding to dissociating agents was evaluated by treating the ELISA wells, after serum incubation with 2 M urea or 0.6 M NaCl for 10 min. An anti-beta2-glycoprotein-I (beta2-GPI) ELISA was used to assess serum reactivity against beta2-GPI, a plasma protein considered as the true antigen of aCL antibodies occurring in APS and SLE patients. The prevalence of aCL, aPS, aPI and aPC antibodies in HIV-1 infection was 36%, 56%, 34% and 43% respectively, which was comparable to that found in SLE/APS and PAPS patients and significantly higher than that observed in SLE/non-APS patients. Anti-beta2-GPI antibodies occurred in 5% of HIV-1 infected vs. 17% in SLE/non-APS (P=0.11), 50% in SLE/APS (P=0.009) and 70% in PAPS patients (P=0.0014). A significant decrease of aPL binding after urea and NaCl treatment was observed in the sera of HIV-1-infected, compared to that of APS patients, indicating that aPL antibodies from HIV-1 infected individuals have low resistance to dissociating agents. In conclusion, aPL antibodies (1) occur in HIV-1 infection; (2) tend to recognize various phospholipids but not beta2-GPI; and (3) are of low resistance to dissociating agents-a finding probably reflecting low antibody avidity. Finally, these, like the autoimmune-type aCL antibodies, tend to recognize the oxidized CL-a finding probably indicating autoantibody generation as a result of neoepitope formation by oxidized PLs. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10550222     DOI: 10.1006/jaut.1999.0324

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  29 in total

Review 1.  Antiphospholipid antibodies and infections.

Authors:  R A Asherson; R Cervera
Journal:  Ann Rheum Dis       Date:  2003-05       Impact factor: 19.103

Review 2.  Infections and the antiphospholipid syndrome.

Authors:  Mario García-Carrasco; Claudio Galarza-Maldonado; Claudia Mendoza-Pinto; Ricardo O Escarcega; Ricard Cervera
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

3.  Immunization with hybrid proteins containing the membrane proximal external region of HIV-1.

Authors:  Nicola Strasz; Vladimir A Morozov; Jürgen Kreutzberger; Martina Keller; Magdalena Eschricht; Joachim Denner
Journal:  AIDS Res Hum Retroviruses       Date:  2014-02-07       Impact factor: 2.205

Review 4.  The antiphospholipid syndrome and infection.

Authors:  G N Dalekos; K Zachou; C Liaskos
Journal:  Curr Rheumatol Rep       Date:  2001-08       Impact factor: 4.592

5.  Serum concentrations of antiphospholipid and anticardiolipin antibodies are higher in HIV-infected women.

Authors:  Alireza Abdollahi; Afsaneh Morteza
Journal:  Rheumatol Int       Date:  2011-03-30       Impact factor: 2.631

6.  B cell responses to HIV-1 infection and vaccination: pathways to preventing infection.

Authors:  Barton F Haynes; M Anthony Moody; Hua-Xin Liao; Laurent Verkoczy; Georgia D Tomaras
Journal:  Trends Mol Med       Date:  2010-11-26       Impact factor: 11.951

7.  Reactivity profiles of broadly neutralizing anti-HIV-1 antibodies are distinct from those of pathogenic autoantibodies.

Authors:  Harvir Singh; Kevin A Henry; Sampson S T Wu; Andrzej Chruscinski; Paul J Utz; Jamie K Scott
Journal:  AIDS       Date:  2011-06-19       Impact factor: 4.177

8.  Antiphospholipid antibodies in HIV-positive patients.

Authors:  Liliana Galrão; Carlos Brites; Maria Luíza Atta; Ajax Atta; Isabella Lima; Fernanda Gonzalez; Fernanda Magalhães; Mittermayer Santiago
Journal:  Clin Rheumatol       Date:  2007-02-28       Impact factor: 2.980

9.  Altered Ratio of T Follicular Helper Cells to T Follicular Regulatory Cells Correlates with Autoreactive Antibody Response in Simian Immunodeficiency Virus-Infected Rhesus Macaques.

Authors:  Wenjin Fan; Andrew James Demers; Yanmin Wan; Qingsheng Li
Journal:  J Immunol       Date:  2018-04-02       Impact factor: 5.422

Review 10.  Anti-phospholipid Antibodies and Smoking: An Overview.

Authors:  Steven R Binder; Christine M Litwin
Journal:  Clin Rev Allergy Immunol       Date:  2017-08       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.